“Roadman Investments Corp.
Bridging the gap to better investment opportunities
Roadman Investments is a Canadian venture capital and advisory firm listed on the TSX Venture Exchange ( TSXV:LITT )( FWB:1QD ). Roadman strives to actively drive innovation and accelerate growth within its portfolio holdings, with the objective of realizing alpha returns. Roadman is mandated with deploying investment capital and advisory services to both public and private companies. Roadman’s investment committee looks to identify companies with a strong potential for accretive revenue and profitability in the following sectors:
Health & Wellness
Roadman Investments is a research-driven investment firm and each portfolio selection goes through methodical analysis. The company uses a broad spectrum of investment strategies across industries and capitalization ranges.
A cornerstone of our philosophy lies in the consistent application of a rigorous investment approach that analyzes not only the financial and business prospects of the companies we invest in but also the the fundamental macro drivers of the industry. The vision and talent of the founders is the drive behind the company and one of our most important considerations. Roadman Investments only partners with entrepreneurs that are highly competent and committed. Our culture stresses teamwork and the free exchange of ideas among our executives and key industry experts to ensure calculated and data driven decisions.
Roadman Investments strives for excellence in portfolio selection, strategic capital allocation and its ability to surpass our partner’s expectations.
Roadman plans to achieve significant growth by investing in securities of companies engaged in health and wellness, nutrition, new forms of medicines, pharmaceutical products and others. In the near term Roadman aims to acquire assets in cultivation, distribution, consumer products and research and development in the medicinal mushroom sector.
The firm’s most distinctive strength is its proprietary, independent research and it’s connections to leading experts in the medicinal mushroom industry. It is this comprehensive approach that is positioning Roadman as a future frontrunner in the fast growing alternative health industry.
Health & Wellness
The world is becoming more health conscious than ever before and wellness needs are growing daily. In pursuit of a more preventative approach to staying healthy, consumers are opting for more conscious nutritional and drug alternatives. Roadman believes that the future of the $4.2 trillion worldwide wellness market relies on appealing to the population that seeks pharmaceutical free alternatives and more natural cures.
Roadman is committed to investing in breakthrough products, devices, treatments and health supplements that promote holistic health and wellness.
CLOV Biopharma Corp (“CBP”) was formed in early 2020 as the specific domicile for the advancement of research, development, and assessment of potential commercial viability of cedar leaf oil and cedar leaf oil vapour in the pharmaceutical, healthcare, and biotechnology sectors.
Backed by over a decade of both in-field studies alongside laboratory and scientific research by foremost Canadian virologist, Dr. James Hudson, PhD.
CBP is party to a licensing agreement whereby it has been granted Intellectual Property consisting of certain products that may be patented, including certain know-how, industry knowledge and experience relating to cedar leaf oil; including preferential access to premium cedar leaf oil.
CBP’s corporate mission is to conduct further R&D of cedar leaf oil vapour for the purposes of preventing the spread of coronavirus and other similar potentially pathogenic respiratory viruses, for example, influenza and para-influenza viruses, and respiratory syncytial viruses.
The Roadman Team
Roadman Investments management team is composed of investment professionals that bring extensive experience in entrepreneurship, venture capital and investment management. The company is also proactively engaging the most renowned leaders in the alternative health industry to ensure access to superior investment opportunities.
Luke Montaine – CEO
Experienced capital markets professional with a 15+ year history in various capacities including the roles of Investment Advisor, Corporate Development and Corporate Finance. Mr. Montaine and has raised millions of dollars in funding for public and private companies and has completed several successful mergers and acquisitions.
David Yoo – CFO
Experienced Chief Financial Officer with a demonstrated 20+ year history of working in the investment management industry. Skilled in Investor Relations, Venture Capital, Equities, Private Equity, and Corporate Finance. Mr. Yoo holds an MBA in Finance and Accounting from New York University, Stern School of Business and a B.A. in Psychology and Economics from the University of California, Berkley.
David Rokoss – Director
Experienced Entrepreneur and Executive with a 20+ year history of working with a variety of private and publicly listed companies. David successfully founded and developed three private retail concepts which grew to more than two dozen locations across western Canada and the United States and has considerable experience in cross-border mergers, corporate acquisitions and compliance. For the last decade, he has consulted with numerous early stage companies across the retail, clean tech, energy and technology sectors, focusing on business and corporate development opportunities.
Min Kuang – Director
Experienced executive with 20 + year history in managing public companies, mergers and acquisitions, business development, and investment management. Ms. Kuang has been involved in a wide range of technology M&A, joint ventures, and other strategic alliance transactions for media , consumer, resource, medical device, and healthcare companies in China and Canada. Ms. Kuang received an M.B.A. from Lawrence Technology University in Michigan and a B.A. degree from China.
Anton Gomez – Strategic Advisor
Mr. Gomez-Escolar is a psychopharmacology specialist that has a Masters in Psychopharmacology from Spain’s largest university Complutense University of Madrid, including a Master Thesis on the topic of “Psychedelics in psychotherapy for the treatment of depression and addiction”, a Masters in International Relations by Griffith University from Australia, and many other diplomas including a certificate of Design and Interpretation of Clinical Trials from John Hopkins School of Public Health, a certificate in Drug Discovery, Development & Commercialization from UCSD and a certificate in Drug Use, Policy and Health from the University of Geneva. His technical understanding of neurobiology, psychopharmacology, drug safety and clinical trial development will allow Roadman Investments to better evaluate potential investments in biotech firms as well as help the company provide advisory services to future investee’s or partners that need this expertise.
Roadman leverages the following investment criteria when evaluating potential investment opportunities:
Exposure to emerging industries primed for geometric growth
Ability to generate alpha returns
Strong potential for accretive revenue and profitability
Evidence of potential dominance in market segment and/or geographic location
Why partner with us?
Roadman Investment’s delivers significant value to entrepreneurs not just with the capital we provide but also with our team’s experience and passion.
Ready to Grow your Business?
Our investment team is always looking for new companies to partner with. If your business requires capital to scale or you are ready for an exit we can help.
Start exploring your options and contact us today!
Why Invest in an Investment Firm?
Being a shareholder of an Investment firm is a natural way to diversify your portfolio and unlock market opportunities not available in traditional asset classes. While traditional asset classes can be an effective source of diversification investors can benefit from having exposure to high growth private companies that would otherwise be not available.
Sign up for our newsletter to download our presentation and learn more about what Roadman has to offer. Our presentation includes information on our:
Investment Philosophy & Criteria
ROADMAN INVESTMENTS SIGNS DEFINITIVE AGREEMENT WITH PSYCHEDELIC INSIGHTS SOLIDIFYING PSYCHEDELICS CLINIC INVESTMENT
Mar 30, 2020
VANCOUVER, British Columbia – Roadman Investments Corp. (TSXV: LITT)(FWB: 1QD) (“Roadman Investments” or the “Company”) is pleased to announce the signing of a definitive agreement with Psychedelic Insights to form a joint venture for the purpose of opening up a legal psychedelic treatment center in the state of California upon the legalization or medical approval of psilocybin.
SHANGHAI INGREDEINTS CORP ISSUES FIRST PURCASE ORDER FOR CLOV CEDAR LEAF OIL FOR DISTRIBUTION IN ASIA IN ITS EFFORTS TO HELP WITH THE RECENT COVID-19 OUTBREAK
Mar 26, 2020
VANCOUVER, British Columbia – Roadman Investments Corp. (TSXV: LITT)(FWB: 1QD)(OTC: RMANF) (“Roadman Investments” or the “Company”) is pleased to announce that the Company has received a purchase order for 10,000 mL of it’s CLOV Biopharma Corp. (CBP) cedar leaf oil from it’s Hong Kong based distribution partner Shanghai Ingredients Trading Limited (“Shanghai Ingredients”) to be distributed across it’s online proprietary sales platforms.
ROADMAN APPOINTS DR. JAMES HUDSON, PH.D TO SCIENTIFIC ADVISORY BOARD
Mar 11, 2020
VANCOUVER, British Columbia – Roadman Investments Corp. (TSXV: LITT)(FWB: 1QD)(OTC: RMANF) (“Roadman Investments” or the “Company”) is pleased to announce that, in connection with Roadman’s recent acquisition of CLOV Biopharma Corp. (“CBP”), Dr. James Hudson, Ph.D has been appointed to the Company’s Scientific Advisory Board effective immediately.
View All News”
Learn more at https://roadmancorp.com/